Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: a double-blind, randomised controlled clinical trial of efficacy and safety.

Nathanson D, Ullman B, Löfström U, Hedman A, Frick M, Sjöholm A, Nyström T

Diabetologia13 Jan 2012Cited by 84 (Europe PMC)

PMID22246377DOI10.1007/s00125-011-2440-xPepBankPUB-22246377

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanRandomized controlled trialEfficacy outcome
In men with diabetes and heart failure, exenatide increased cardiac index compared with placebo.
In plain wordsIn men with diabetes and heart failure, exenatide increased cardiac index compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseCardiac index
Study
n = 20
Comparator
Placebo
Analysis
Primary
Outcome group
Heart function · Cardiovascular
Studied dose
0.12 pmol/kg/min · intravenous · 6 hAs given in this study (human).
Measurements
Cardiac index change
0.4 l min(-1) m(-2)
exenatide, 3 h
Cardiac index change
23%
exenatide, 3 h
Cardiac index change
0.33 l min(-1) m(-2)
exenatide, 6 h
Cardiac index change
17%
exenatide, 6 h
Cardiac index change
−0.02 l min(-1) m(-2)
placebo, 3 h
Cardiac index change
−1%
placebo, 3 h
Cardiac index change
−0.08 l min(-1) m(-2)
placebo, 6 h
Cardiac index change
−5%
placebo, 6 h
Source sentences
Summary
CI increased at 3 and 6 h by 0.4 ± 0.1 (23%) and 0.33 ± 0.1 (17%) l min(-1) m(-2), during exenatide infusion vs -0.02 ± 0.1 (-1%) and -0.08 ± 0.1 (-5%) l min(-1) m(-2) during placebo (p = 0.003);
1 context sentence(design, population, supporting numbers)
Summary · context
Out of 237 patients screened, 20 male type 2 diabetic patients participated in this crossover trial design and were allocated (sequentially numbered) to i.v. infusions during two consecutive days with (1) exenatide (0.12 pmol/kg/min); and (2) placebo for 6 h followed by a washout period for 18 h, at…
Report a problemFND-2224637701
02HumanRandomized controlled trialEfficacy outcome
In men with diabetes and heart failure, exenatide decreased pulmonary capillary wedge pressure compared with placebo.
In plain wordsIn men with diabetes and heart failure, exenatide decreased lung capillary pressure compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreasePulmonary capillary wedge pressure
Study
n = 20
Comparator
Placebo
Analysis
Primary
Outcome group
Heart function · Cardiovascular
Studied dose
0.12 pmol/kg/min · intravenous · 6 hAs given in this study (human).
Measurements
PCWP change
−1.3 mmHg
exenatide, 1 h
PCWP change
−8%
exenatide, 1 h
PCWP change
0.3 mmHg
placebo, 1 h
PCWP change
2%
placebo, 1 h
PCWP change
−1.2 mmHg
exenatide, 3 h
PCWP change
−8%
exenatide, 3 h
PCWP change
1 mmHg
placebo, 3 h
PCWP change
6%
placebo, 3 h
4 more measurements in the study.
Source sentences
Summary
PCWP decreased at 1, 3 and 6 h by -1.3 ± 0.8 (-8%), -1.2 ± 1 (-8%) and -2.2 ± 0.9 (-15%) mmHg, during exenatide infusion vs 0.3 ± 0.5 (2%), 1 ± 0.6 (6%) and 1.4 ± 0.7 (8%) mmHg, during placebo (p = 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
Out of 237 patients screened, 20 male type 2 diabetic patients participated in this crossover trial design and were allocated (sequentially numbered) to i.v. infusions during two consecutive days with (1) exenatide (0.12 pmol/kg/min); and (2) placebo for 6 h followed by a washout period for 18 h, at…
Report a problemFND-2224637703
03HumanRandomized controlled trialSafety outcome
In men with diabetes and heart failure, no serious adverse event occurred during the exenatide trial.
In plain wordsIn men with diabetes and heart failure, no serious side effect occurred during the exenatide trial.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableSerious adverse events
Study
n = 20
Analysis
Secondary
Outcome group
Adverse events · Whole body
Studied dose
0.12 pmol/kg/min · intravenous · 6 hAs given in this study (human).
Source sentences
Summary
No serious adverse event was observed.
1 context sentence(design, population, supporting numbers)
Summary · context
Out of 237 patients screened, 20 male type 2 diabetic patients participated in this crossover trial design and were allocated (sequentially numbered) to i.v. infusions during two consecutive days with (1) exenatide (0.12 pmol/kg/min); and (2) placebo for 6 h followed by a washout period for 18 h, at…
Report a problemFND-2224637704
04HumanRandomized controlled trialSafety outcome
In men with diabetes and heart failure, adverse events were reported in nine patients during the exenatide trial.
In plain wordsIn men with diabetes and heart failure, nine patients reported side effects during the exenatide trial.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableAny adverse event
Study
n = 20
Analysis
Secondary
Outcome group
Adverse events · Whole body
Studied dose
0.12 pmol/kg/min · intravenous · 6 hAs given in this study (human).
Measurements
Patients with adverse events
9 patients
exenatide trial
Source sentences
Summary
Adverse events were reported in nine patients (six, nausea; two, increased HR; one, increased systolic blood pressure).
1 context sentence(design, population, supporting numbers)
Summary · context
Out of 237 patients screened, 20 male type 2 diabetic patients participated in this crossover trial design and were allocated (sequentially numbered) to i.v. infusions during two consecutive days with (1) exenatide (0.12 pmol/kg/min); and (2) placebo for 6 h followed by a washout period for 18 h, at…
Report a problemFND-2224637705
05HumanRandomized controlled trialSafety outcome
In men with diabetes and heart failure, six patients reported nausea during the exenatide trial.
In plain wordsIn men with diabetes and heart failure, six patients reported nausea during the exenatide trial.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableNausea
Study
n = 20
Analysis
Secondary
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
0.12 pmol/kg/min · intravenous · 6 hAs given in this study (human).
Measurements
Patients with nausea
6 patients
exenatide trial
Source sentences
Summary
Adverse events were reported in nine patients (six, nausea; two, increased HR; one, increased systolic blood pressure).
1 context sentence(design, population, supporting numbers)
Summary · context
Out of 237 patients screened, 20 male type 2 diabetic patients participated in this crossover trial design and were allocated (sequentially numbered) to i.v. infusions during two consecutive days with (1) exenatide (0.12 pmol/kg/min); and (2) placebo for 6 h followed by a washout period for 18 h, at…
Report a problemFND-2224637706
06HumanRandomized controlled trialSafety outcome
In men with diabetes and heart failure, two patients reported increased heart rate during the exenatide trial.
In plain wordsIn men with diabetes and heart failure, two patients reported increased heart rate during the exenatide trial.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableIncreased heart rate adverse event
Study
n = 20
Analysis
Secondary
Outcome group
Adverse events · Cardiovascular
Studied dose
0.12 pmol/kg/min · intravenous · 6 hAs given in this study (human).
Measurements
Patients with increased heart rate
2 patients
exenatide trial
Source sentences
Summary
Adverse events were reported in nine patients (six, nausea; two, increased HR; one, increased systolic blood pressure).
1 context sentence(design, population, supporting numbers)
Summary · context
Out of 237 patients screened, 20 male type 2 diabetic patients participated in this crossover trial design and were allocated (sequentially numbered) to i.v. infusions during two consecutive days with (1) exenatide (0.12 pmol/kg/min); and (2) placebo for 6 h followed by a washout period for 18 h, at…
Report a problemFND-2224637707
07HumanRandomized controlled trialSafety outcome
In men with diabetes and heart failure, one patient reported increased systolic blood pressure during the exenatide trial.
In plain wordsIn men with diabetes and heart failure, one patient reported increased systolic blood pressure during the exenatide trial.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableIncreased systolic blood pressure adverse event
Study
n = 20
Analysis
Secondary
Outcome group
Adverse events · Cardiovascular
Studied dose
0.12 pmol/kg/min · intravenous · 6 hAs given in this study (human).
Measurements
Patients with increased systolic blood pressure
1 patients
exenatide trial
Source sentences
Summary
Adverse events were reported in nine patients (six, nausea; two, increased HR; one, increased systolic blood pressure).
1 context sentence(design, population, supporting numbers)
Summary · context
Out of 237 patients screened, 20 male type 2 diabetic patients participated in this crossover trial design and were allocated (sequentially numbered) to i.v. infusions during two consecutive days with (1) exenatide (0.12 pmol/kg/min); and (2) placebo for 6 h followed by a washout period for 18 h, at…
Report a problemFND-2224637708
08HumanRandomized controlled trialEfficacy outcome
In men with diabetes and heart failure, exenatide increased heart rate compared with placebo.
In plain wordsIn men with diabetes and heart failure, exenatide increased heart rate compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseHeart rate
Study
n = 20
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
0.12 pmol/kg/min · intravenous · 6 hAs given in this study (human).
Measurements
Heart rate change
8 beats min(-1)
exenatide, 1 h
Heart rate change
11%
exenatide, 1 h
Heart rate change
−1 beats min(-1)
placebo, 1 h
Heart rate change
−2%
placebo, 1 h
Heart rate change
15 beats min(-1)
exenatide, 3 h
Heart rate change
21%
exenatide, 3 h
Heart rate change
1 beats min(-1)
placebo, 3 h
Heart rate change
2%
placebo, 3 h
4 more measurements in the study.
Source sentences
Summary
heart rate (HR) increased at 1, 3 and 6 h by 8 ± 3 (11%), 15 ± 4 (21%) and 21 ± 5 (29%) beats per min (bpm), during exenatide infusion vs -1 ± 2 (-2%), 1 ± 1 (2%) and 6 ± 2 (8%) bpm, during placebo (p = 0.006);
1 context sentence(design, population, supporting numbers)
Summary · context
Out of 237 patients screened, 20 male type 2 diabetic patients participated in this crossover trial design and were allocated (sequentially numbered) to i.v. infusions during two consecutive days with (1) exenatide (0.12 pmol/kg/min); and (2) placebo for 6 h followed by a washout period for 18 h, at…
Report a problemFND-2224637702

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4NCT02655770

Effect of Liraglutide on Diastolic Dysfunction on Cardiac MRI in Type 2 Diabetes Patients

Copenhagen University Hospital, Rigshospitaletn = 40Feb 2016 to Dec 2019

Diabetes Mellitus Type 2 · Diastolic Dysfunction · Cardiac MRI · Myocardial Perfusion

Trial page ClinicalTrials.govUpdated 14 Jan 2021

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.